M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma
Jennifer Clarke,Annette M. Molinaro,Juan R. Cabrera,Ashley A. DeSilva,Jane Rabbitt,Joshua Prey,Daryl C. Drummond,Jaeyeon Kim,Charles O. Noble,Jonathan Fitzgerald,Susan M. Chang,Nicholas Butowski,Jennie Taylor,John W. Park,Michael D. Prados +14 more
TL;DR: Nal-IRI had no unexpected toxicities when given intravenously and the maximum tolerated dose (MTD) in patients with recurrent high-grade glioma stratified based on UGT1A1 genotyping was determined.
Journal ArticleDOI
Combined BRAF V600E and MEK blockade for BRAF V600E -mutant gliomas
Jie Zhang,Tsun-Wen Yao,Rintaro Hashizume,Sujatmi Hariono,Krister J. Barkovich,Qi-Wen Fan,Michael D. Prados,C. David James,William A. Weiss,Theodore Nicolaides +9 more
TL;DR: In glioma, recovery of MAPK signaling upon BRAF inhibition accounts for intrinsic resistance to BRAFV600E inhibitor, resulting in enhanced antitumor efficacy and also reduces the risk of secondary malignancy development.
Journal ArticleDOI
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Luis A. Rodriguez,Michael D. Prados,Dorcas Fulton,Michael S. B. Edwards,Pamela Silver,Victor A. Levin +5 more
TL;DR: Patients with cerebellar, thalamic, and spinal cord tumors did very well, with an 87% response or stabilization of disease and a median TTP of 122 weeks.
Journal ArticleDOI
A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma
Phioanh L. Nghiemphu,Patrick Y. Wen,Kathleen R. Lamborn,Jan Drappatz,H. Ian Robins,Karen Fink,Mark G. Malkin,Frank S. Lieberman,Lisa M. DeAngelis,Alejandro Torres-Trejo,Susan M. Chang,Lauren E. Abrey,Howard A. Fine,Alexis Demopoulos,Andrew B. Lassman,Santosh Kesari,Minesh P. Mehta,Michael D. Prados,Timothy F. Cloughesy +18 more
TL;DR: Tipifarnib is well tolerated at 300 mg bid given discontinuously in 4-week cycles, concurrently with standard chemo/radiotherapy, in patients with newly diagnosed glioblastoma and not receiving EIAED.
Journal Article
Future directions in the treatment of malignant gliomas with temozolomide.
TL;DR: The mechanism of action of TMZ and strategies for overcoming pathways of resistance to this promising agent, including the use of TMZ in combination with other chemotherapeutic agents or radiation therapy, and exploration of alternate dosing schedules are discussed.